Download PDF
Facial Plast Surg 2014; 30(01): 016-025
DOI: 10.1055/s-0034-1365824
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Treatment of Unwanted Pigment

Elizabeth W. Chance
1   Department of Plastic Surgery, Martha Jefferson Hospital, Charlottesville, Virginia
› Author Affiliations
Further Information

Publication History

Publication Date:
31 January 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Disorders of skin pigmentation pose significant challenges to both patients and physicians, as they have the unfortunate duality of being both common and difficult to treat conditions. This article reviews the etiology, pathophysiology, clinical presentation, and treatment options for melasma and postinflammatory hyperpigmentation. A thorough understanding of the disease process itself, expected agent efficacy, risks, and benefits of various treatments is crucial while treating these complex conditions.

Keywords

solar lentigines - melasma - postinflammatory hyperpigmentation
 

  • References

  • 1 Ortonne JP. Pigmentary changes of the ageing skin. Br J Dermatol 1990; 122 (Suppl. 35) 21-28
    PubMedGoogle Scholar
  • 2 Schaffer JV, Bolognia JL. The clinical spectrum of pigmented lesions. Clin Plast Surg 2000; 27 (3) 391-408 , viii
    PubMedGoogle Scholar
  • 3 Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol 1995; 131 (12) 1453-1457
    CrossrefPubMedGoogle Scholar
  • 4 Ortonne JP, Arellano I, Berneburg M , et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol 2009; 23 (11) 1254-1262
    CrossrefPubMedGoogle Scholar
  • 5 Sivayathorn A. Melasma in Orientas. Clin Drug Investig 1995; 10 (Suppl. 02) 34-40
    CrossrefPubMedGoogle Scholar
  • 6 Werlinger KD, Guevara IL, González CM , et al. Prevalence of self-diagnosed melasma among premenopausal Latino women in Dallas and Fort Worth, Tex. Arch Dermatol 2007; 143 (3) 424-425
    PubMedGoogle Scholar
  • 7 Freitag FM, Cestari TF, Leopoldo LR, Paludo P, Boza JC. Effect of melasma on quality of life in a sample of women living in southern Brazil. J Eur Acad Dermatol Venereol 2008; 22 (6) 655-662
    CrossrefPubMedGoogle Scholar
  • 8 Kulthanan K. Pigmentary disorders. In: Kullavanijaya P, Pisalbutra P, , eds. Dermatology 2010. Bangkok: Holistic Publishing; 2005
    Google Scholar
  • 9 Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol 2010; 3 (7) 20-31
    PubMedGoogle Scholar
  • 10 Takiwaki H, Shirai S, Kohno H, Soh H, Arase S. The degrees of UVB-induced erythema and pigmentation correlate linearly and are reduced in a parallel manner by topical anti-inflammatory agents. J Invest Dermatol 1994; 103 (5) 642-646
    CrossrefPubMedGoogle Scholar
  • 11 Cardinali G, Kovacs D, Picardo M. Mechanisms underlying post-inflammatory hyperpigmentation: lessons from solar lentigo. Ann Dermatol Venereol 2012; 139 (4) S148-S152
    CrossrefPubMedGoogle Scholar
  • 12 Montagna W, Hu F, Carlisle K. A reinvestigation of solar lentigines. Arch Dermatol 1980; 116 (10) 1151-1154
    CrossrefPubMedGoogle Scholar
  • 13 Kang WH, Yoon KH, Lee ES , et al. Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol 2002; 146 (2) 228-237
    CrossrefPubMedGoogle Scholar
  • 14 Lee DJ, Lee J, Ha J, Park KC, Ortonne JP, Kang HY. Defective barrier function in melasma skin. J Eur Acad Dermatol Venereol 2012; 26 (12) 1533-1537
    PubMedGoogle Scholar
  • 15 Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. J Dermatol Sci 2007; 46 (2) 111-116
    CrossrefPubMedGoogle Scholar
  • 16 Ruiz-Maldonado R, Orozco-Covarrubias ML ; Ruiz-Maldonado R. Postinflammatory hypopigmentation and hyperpigmentation. Semin Cutan Med Surg 1997; 16 (1) 36-43
    CrossrefPubMedGoogle Scholar
  • 17 Moin A, Jabery Z, Fallah N. Prevalence and awareness of melasma during pregnancy. Int J Dermatol 2006; 45 (3) 285-288
    CrossrefPubMedGoogle Scholar
  • 18 Cestari T, Arellano I, Hexsel D, Ortonne JP ; Latin American Pigmentary Disorders Academy. Melasma in Latin America: options for therapy and treatment algorithm. J Eur Acad Dermatol Venereol 2009; 23 (7) 760-772
    CrossrefPubMedGoogle Scholar
  • 19 Nordlund JJ, Abdel-Malek ZA. Mechanisms for post-inflammatory hyperpigmentation and hypopigmentation. Prog Clin Biol Res 1988; 256: 219-236
    PubMedGoogle Scholar
  • 20 Tomita Y, Maeda K, Tagami H. Melanocyte-stimulating properties of arachidonic acid metabolites: possible role in postinflammatory pigmentation. Pigment Cell Res 1992; 5 (5 Pt 2) 357-361
    CrossrefPubMedGoogle Scholar
  • 21 O'Brien TJ, Dyall-Smith D, Hall AP. Melasma on the forearms. Australas J Dermatol 1997; 38 (1) 35-37
    CrossrefPubMedGoogle Scholar
  • 22 McDonald RR, Georgouras KE. Skin disorders in Indo-Chinese immigrants. Med J Aust 1992; 156 (12) 847-853
    PubMedGoogle Scholar
  • 23 Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, Mihm Jr MC. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol 1981; 4 (6) 698-710
    CrossrefPubMedGoogle Scholar
  • 24 Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol 2005; 27 (2) 96-101
    CrossrefPubMedGoogle Scholar
  • 25 Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol 2006; 55 (6) 1048-1065
    CrossrefPubMedGoogle Scholar
  • 26 Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol 2006; 54 (5) (Suppl. 02) S272-S281
    CrossrefPubMedGoogle Scholar
  • 27 Rigopoulos D, Gregoriou S, Katsambas A. Hyperpigmentation and melasma. J Cosmet Dermatol 2007; 6 (3) 195-202
    CrossrefPubMedGoogle Scholar
  • 28 Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma. Cochrane Database Syst Rev 2010; 7 (7) CD003583
    PubMedGoogle Scholar
  • 29 Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg 2009; 28 (2) 77-85
    CrossrefPubMedGoogle Scholar
  • 30 Taylor SC, Grimes PE, Rahman Z , et al. Acne vulgrais in skin of color. J Am Acad Dermatol 2002; 46(2): S98-S106
    CrossrefPubMedGoogle Scholar
  • 31 Guerrero D. Dermocosmetic management of hyperpigmentations. Ann Dermatol Venereol 2012; 139 (4) S166-S169
    CrossrefPubMedGoogle Scholar
  • 32 Lakhdar H, Zouhair K, Khadir K , et al. Evaluation of the effectiveness of broad-spectrum sunscreen in the prevention of cholasma in pregnant women. J Eur Acad Dermatol Venereol 2007; 21 (6) 738-742
    CrossrefPubMedGoogle Scholar
  • 33 Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol 2011; 65 (4) 699-714 , quiz 715
    CrossrefPubMedGoogle Scholar
  • 34 Draelos Z. Hydroquinone:optimizing therapeutic outcomes in the clinical setting of melanin-related hyperpigmentation. Today's Therapeutic Trends 2001; 19: 191-203
    PubMedGoogle Scholar
  • 35 Tse TW. Hydroquinone for skin lightening: safety profile, duration of use and when should we stop?. J Dermatolog Treat 2010; 21 (5) 272-275
    CrossrefPubMedGoogle Scholar
  • 36 Zawar VP, Mhaskar ST. Exogenous ochronosis following hydroquinone for melasma. J Cosmet Dermatol 2004; 3 (4) 234-236
    CrossrefPubMedGoogle Scholar
  • 37 Westerhof W, Kooyers TJ. Hydroquinone and its analogues in dermatology - a potential health risk. J Cosmet Dermatol 2005; 4 (2) 55-59
    CrossrefPubMedGoogle Scholar
  • 38 Levitt J. The safety of hydroquinone: a dermatologist's response to the 2006 Federal Register. J Am Acad Dermatol 2007; 57 (5) 854-872
    CrossrefPubMedGoogle Scholar
  • 39 Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Eur Acad Dermatol Venereol 2006; 20 (7) 781-787
    CrossrefPubMedGoogle Scholar
  • 40 Deisinger PJ, Hill TS, English JC. Human exposure to naturally occurring hydroquinone. J Toxicol Environ Health 1996; 47 (1) 31-46
    CrossrefPubMedGoogle Scholar
  • 41 Fleischer Jr AB, Schwartzel EH, Colby SI, Altman DJ. The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies. J Am Acad Dermatol 2000; 42 (3) 459-467
    CrossrefPubMedGoogle Scholar
  • 42 Jarratt M. Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Cutis 2004; 74 (5) 319-322
    PubMedGoogle Scholar
  • 43 Draelos ZD. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin effectively improves the appearance of solar lentigines in ethnic groups. J Cosmet Dermatol 2006; 5 (3) 239-244
    CrossrefPubMedGoogle Scholar
  • 44 Taylor SC, Callender VD. A multicenter, 12-week, phase 3b trial: a combination solution of mequinol 2%/tretinoin 0.01% vs hydroquinone 4% cream in the treatment of mild to moderate postinflammatory hyperpigmentation [abstract]. J Am Acad Dermatol 2006; 54 (Suppl): AB194
    PubMedGoogle Scholar
  • 45 Ortonne JP, Pandya AG, Lui H, Hexsel D. Treatment of solar lentigines. J Am Acad Dermatol 2006; 54 (5) (Suppl. 02) S262-S271
    CrossrefPubMedGoogle Scholar
  • 46 Taylor SC, Burgess CM, Callender VD , et al. Postinflammatory hyperpigmentation: evolving combination treatment strategies. Cutis 2006; 78 (2) (Suppl. 02) 6-19
    PubMedGoogle Scholar
  • 47 Keeling J, Cardona L, Benitez A, Epstein R, Rendon M. Mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men: a case series and review of the literature. Cutis 2008; 81 (2) 179-183
    PubMedGoogle Scholar
  • 48 Piacquadio D, Farris P, Downie J , et al. Mequinol 2%/tretinoin 0.01% solution monotherapy and combination treatment of solar lentigines and postinflammatory hyperpigmentation [poster]. J Am Acad Dermatol 2005; 52 (Suppl): 145
    CrossrefPubMedGoogle Scholar
  • 49 Griffiths CE, Finkel LJ, Tranfaglia MG, Hamilton TA, Voorhees JJ. An in vivo experimental model for effects of topical retinoic acid in human skin. Br J Dermatol 1993; 129 (4) 389-394
    CrossrefPubMedGoogle Scholar
  • 50 Roméro C, Aberdam E, Larnier C, Ortonne JP. Retinoic acid as modulator of UVB-induced melanocyte differentiation. Involvement of the melanogenic enzymes expression. J Cell Sci 1994; 107 (Pt 4) 1095-1103
    PubMedGoogle Scholar
  • 51 Dogra S, Kanwar AJ, Parsad D. Adapalene in the treatment of melasma: a preliminary report. J Dermatol 2002; 29 (8) 539-540
    PubMedGoogle Scholar
  • 52 Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK , et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med 1993; 328 (20) 1438-1443
    CrossrefPubMedGoogle Scholar
  • 53 Kang S, Goldfarb MT, Weiss JS , et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. J Am Acad Dermatol 2003; 49 (1) 83-90
    CrossrefPubMedGoogle Scholar
  • 54 Jacyk WK. Adapalene in the treatment of African patients. J Eur Acad Dermatol Venereol 2001; 15 (Suppl. 03) 37-42
    CrossrefPubMedGoogle Scholar
  • 55 Pathak MA, Fitzpatrick TB, Kraus EW. Usefulness of retinoic acid in the treatment of melasma. J Am Acad Dermatol 1986; 15 (4 Pt 2) 894-899
    CrossrefPubMedGoogle Scholar
  • 56 Cook-Bolden FE, Hamilton SF. An open-label study of the efficacy and tolerability of microencapsulated hydroquinone 4% and retinol 0.15% with antioxidants for the treatment of hyperpigmentation. Cutis 2008; 81 (4) 365-371
    PubMedGoogle Scholar
  • 57 Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis 2004; 74 (6) 362-368
    PubMedGoogle Scholar
  • 58 Callender VD. Acne in ethnic skin: special considerations for therapy. Dermatol Ther 2004; 17 (2) 184-195
    CrossrefPubMedGoogle Scholar
  • 59 Taylor SC, Torok H, Jones T , et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 2003; 72 (1) 67-72
    PubMedGoogle Scholar
  • 60 Ferreira Cestari T, Hassun K, Sittart A, de Lourdes Viegas M. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol 2007; 6 (1) 36-39
    CrossrefPubMedGoogle Scholar
  • 61 Chan R, Park KC, Lee MH , et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol 2008; 159 (3) 697-703
    PubMedGoogle Scholar
  • 62 Rossi AM, Perez MI. Treatment of hyperpigmentation. Facial Plast Surg Clin North Am 2011; 19 (2) 313-324
    CrossrefPubMedGoogle Scholar
  • 63 Fitton A, Goa KL. Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 1991; 41 (5) 780-798
    CrossrefPubMedGoogle Scholar
  • 64 Lowe NJ, Rizk D, Grimes P, Billips M, Pincus S. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther 1998; 20 (5) 945-959
    CrossrefPubMedGoogle Scholar
  • 65 Farshi S. Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma. J Cosmet Dermatol 2011; 10 (4) 282-287
    CrossrefPubMedGoogle Scholar
  • 66 Baliña LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol 1991; 30 (12) 893-895
    CrossrefPubMedGoogle Scholar
  • 67 Rosfarizan M, Ariff AB. Kinetics of kojic acid fermentation by Aspergillus Flavus using different types of concentrations of carbon and nitrogen sources. J Ind Micro Bio Tech 2000; 25: 20-24
    PubMedGoogle Scholar
  • 68 Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg 1999; 25 (4) 282-284
    CrossrefPubMedGoogle Scholar
  • 69 Garcia A, Fulton Jr JE. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg 1996; 22 (5) 443-447
    CrossrefPubMedGoogle Scholar
  • 70 Nakagawa M, Kawai K, Kawai K. Contact allergy to kojic acid in skin care products. Contact Dermat 1995; 32 (1) 9-13
    CrossrefPubMedGoogle Scholar
  • 71 García-Gavín J, González-Vilas D, Fernández-Redondo V, Toribio J. Pigmented contact dermatitis due to kojic acid. A paradoxical side effect of a skin lightener. Contact Dermatitis 2010; 62: 63-64
    CrossrefPubMedGoogle Scholar
  • 72 Mata TL, Sanchez JP, De La Cuadra Oyanguren J. Allergic contact dermatitis due to kojic acid. Dermatitis 2005; 16 (2) 89 , quiz 55–56
    CrossrefPubMedGoogle Scholar
  • 73 Gage AA, Meenaghan MA, Natiella JR, Greene Jr GW. Sensitivity of pigmented mucosa and skin to freezing injury. Cryobiology 1979; 16 (4) 348-361
    CrossrefPubMedGoogle Scholar
  • 74 Almond-Roesler B, Zouboulis CC, Almond-Roesler B. Successful treatment of solar lentigines by brief gentle cryosurgery using a Kryomed device. Br J Dermatol 2000; 143 (1) 216-218
    CrossrefPubMedGoogle Scholar
  • 75 Zouboulis CC, Rosenberger AD, Adler Y, Orfanos CE. Treatment of solar lentigo with cryosurgery. Acta Derm Venereol 1999; 79 (6) 489-490
    CrossrefPubMedGoogle Scholar
  • 76 Van Scott EJ, Yu RJ. Alpha hydroxy acids: procedures for use in clinical practice. Cutis 1989; 43 (3) 222-228
    PubMedGoogle Scholar
  • 77 Tung RC, Bergfeld WF, Vidimos AT, Remzi BK. Alpha-Hydroxy acid-based cosmetic procedures. Guidelines for patient management. Am J Clin Dermatol 2000; 1 (2) 81-88
    CrossrefPubMedGoogle Scholar
  • 78 Green BA, Yu RJ, Van Scott EJ. Clinical and cosmeceutical uses of hydroxyacids. Clin Dermatol 2009; 27 (5) 495-501
    CrossrefPubMedGoogle Scholar
  • 79 Sarkar R, Bansal S, Garg VK. Chemical peels for melasma in dark-skinned patients. J Cutan Aesthet Surg 2012; 5 (4) 247-253
    CrossrefPubMedGoogle Scholar
  • 80 Burns RL, Prevost-Blank PL, Lawry MA, Lawry TB, Faria DT, Fivenson DP. Glycolic acid peels for postinflammatory hyperpigmentation in black patients. A comparative study. Dermatol Surg 1997; 23 (3) 171-174 , discussion 175
    PubMedGoogle Scholar
  • 81 Cook KK, Cook Jr WR. Chemical peel of nonfacial skin using glycolic acid gel augmented with TCA and neutralized based on visual staging. Dermatol Surg 2000; 26 (11) 994-999
    CrossrefPubMedGoogle Scholar
  • 82 Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid as a new therapeutic peeling agent in melasma. Dermatol Surg 2005; 31 (2) 149-154 , discussion 154
    PubMedGoogle Scholar
  • 83 Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid chemical peels as a new therapeutic modality in melasma in comparison to Jessner's solution chemical peels. Dermatol Surg 2006; 32 (12) 1429-1436
    CrossrefPubMedGoogle Scholar
  • 84 Bari AU, Iqbal Z, Rahman SB. Tolerance and safety of superficial chemical peeling with salicylic acid in various facial dermatoses. Indian J Dermatol Venereol Leprol 2005; 71 (2) 87-90
    CrossrefPubMedGoogle Scholar
  • 85 Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg 1999; 25 (1) 18-22
    CrossrefPubMedGoogle Scholar
  • 86 Ahn HH, Kim IH. Whitening effect of salicylic acid peels in Asian patients. Dermatol Surg 2006; 32 (3) 372-375 , discussion 375
    CrossrefPubMedGoogle Scholar
  • 87 Joshi SS, Boone SL, Alam M , et al. Effectiveness, safety, and effect on quality of life of topical salicylic acid peels for treatment of postinflammatory hyperpigmentation in dark skin. Dermatol Surg 2009; 35 (4) 638-644 , discussion 644
    CrossrefPubMedGoogle Scholar
  • 88 Lawrence N, Cox SE, Brody HJ. Treatment of melasma with Jessner's solution versus glycolic acid: a comparison of clinical efficacy and evaluation of the predictive ability of Wood's light examination. J Am Acad Dermatol 1997; 36 (4) 589-593
    CrossrefPubMedGoogle Scholar
  • 89 Watanabe S. Basics of laser application to dermatology. Arch Dermatol Res 2008; 300 (Suppl. 01) S21-S30
    CrossrefPubMedGoogle Scholar
  • 90 Kauvar AN. The evolution of melasma therapy: targeting melanosomes using low-fluence Q-switched neodymium-doped yttrium aluminium garnet lasers. Semin Cutan Med Surg 2012; 31 (2) 126-132
    CrossrefPubMedGoogle Scholar
  • 91 Wang CC, Hui CY, Sue YM, Wong WR, Hong HS. Intense pulsed light for the treatment of refractory melasma in Asian persons. Dermatol Surg 2004; 30 (9) 1196-1200
    CrossrefPubMedGoogle Scholar
  • 92 Zoccali G, Piccolo D, Allegra P, Giuliani M. Melasma treated with intense pulsed light. Aesthetic Plast Surg 2010; 34 (4) 486-493
    CrossrefPubMedGoogle Scholar
  • 93 Moreno Arias GA, Ferrando J. Intense pulsed light for melanocytic lesions. Dermatol Surg 2001; 27 (4) 397-400
    CrossrefPubMedGoogle Scholar
  • 94 Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by Q-switched ruby laser. J Dermatol Surg Oncol 1994; 20 (9) 592-597
    CrossrefPubMedGoogle Scholar
  • 95 Kopera D, Hohenleutner U. Ruby laser treatment of melasma and postinflammatory hyperpigmentation. Dermatol Surg 1995; 21 (11) 994
    CrossrefPubMedGoogle Scholar
  • 96 Tse Y, Levine VJ, McClain SA, Ashinoff R. The removal of cutaneous pigmented lesions with the Q-switched ruby laser and the Q-switched neodymium: yttrium-aluminum-garnet laser. A comparative study. J Dermatol Surg Oncol 1994; 20 (12) 795-800
    CrossrefPubMedGoogle Scholar
  • 97 Kauvar AN. Successful treatment of melasma using a combination of microdermabrasion and Q-switched Nd:YAG lasers. Lasers Surg Med 2012; 44 (2) 117-124
    CrossrefPubMedGoogle Scholar
  • 98 Kopera D, Hohenleutner U, Landthaler M. Quality-switched a histopathological and immunohistochemical study. Dermatology 1997; 194: 338-343
    CrossrefPubMedGoogle Scholar
  • 99 Sadighha A, Saatee S, Muhaghegh-Zahed G. Efficacy and adverse effects of Q-switched ruby laser on solar lentigines: a prospective study of 91 patients with Fitzpatrick skin type II, III, and IV. Dermatol Surg 2008; 34 (11) 1465-1468
    CrossrefPubMedGoogle Scholar
  • 100 Tierney EP, Hanke CW. Review of the literature: Treatment of dyspigmentation with fractionated resurfacing. Dermatol Surg 2010; 36 (10) 1499-1508
    CrossrefPubMedGoogle Scholar
  • 101 Rokhsar CK, Fitzpatrick RE. The treatment of melasma with fractional photothermolysis: a pilot study. Dermatol Surg 2005; 31 (12) 1645-1650
    CrossrefPubMedGoogle Scholar
  • 102 Goldberg DJ, Berlin AL, Phelps R. Histologic and ultrastructural analysis of melasma after fractional resurfacing. Lasers Surg Med 2008; 40 (2) 134-138
    CrossrefPubMedGoogle Scholar
  • 103 Tannous ZS, Astner S. Utilizing fractional resurfacing in the treatment of therapy-resistant melasma. J Cosmet Laser Ther 2005; 7 (1) 39-43
    CrossrefPubMedGoogle Scholar
  • 104 Naito SK. Fractional photothermolysis treatment for resistant melasma in Chinese females. J Cosmet Laser Ther 2007; 9 (3) 161-163
    CrossrefPubMedGoogle Scholar
  • 105 Kroon MW, Wind BS, Beek JF , et al. Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study. J Am Acad Dermatol 2011; 64 (3) 516-523
    CrossrefPubMedGoogle Scholar
  • 106 Karsai S, Fischer T, Pohl L , et al. Is non-ablative 1550-nm fractional photothermolysis an effective modality to treat melasma? Results from a prospective controlled single-blinded trial in 51 patients. J Eur Acad Dermatol Venereol 2012; 26 (4) 470-476
    CrossrefPubMedGoogle Scholar
  • 107 Polder KD, Harrison A, Eubanks LE, Bruce S. 1,927-nm fractional thulium fiber laser for the treatment of nonfacial photodamage: a pilot study. Dermatol Surg 2011; 37 (3) 342-348
    CrossrefPubMedGoogle Scholar
  • 108 Niwa Massaki AB, Eimpunth S, Fabi SG, Guiha I, Groff W, Fitzpatrick R. Treatment of melasma with the 1,927-nm fractional thulium fiber laser: a retrospective analysis of 20 cases with long-term follow-up. Lasers Surg Med 2013; 45 (2) 95-101
    CrossrefPubMedGoogle Scholar
  • 109 Lee HM, Haw S, Kim JK, Chang SE, Lee MW. Split-face study using a 1,927-nm thulium fiber fractional laser to treat photoaging and melasma in Asian skin. Dermatol Surg 2013; 39 (6) 879-888
    CrossrefPubMedGoogle Scholar